Streetbeat News

ENVB

Enveric Biosciences, Inc.

https://www.enveric.com

Industry

Biotechnology

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Open

0.48

Mkt cap

4.2M

Volume

501K

High

0.53

P/E Ratio

-0.14

52-wk high

2.92

Low

0.46

Div yield

N/A

52-wk low

0.36

In Tuesday's after-market session, several healthcare stocks showed significant movement. Etao International Co led the gainers with a 249.4% increase, while Aquestive Therapeutics experienced the largest decline among the losers at 11.4%. Taysha Gene Therapies reported Q4 earnings, contributing to a 29.36% rise in its stock. Other notable movers include Moleculin Biotech, Turnstone Biologics, and Enveric Biosciences on the gainers' side, and Trxade Health, Ontrak, and Virpax Pharmaceuticals among the losers.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 9:34 pm

Enveric Biosciences Canada has been granted U.S. Patent #11931338 for nitrilated psilocybin derivatives and their usage methods. This development could potentially enhance the company's intellectual property portfolio and open new avenues in psychedelic-based treatments.

Portfolio Pulse from Charles Gross

March 19, 2024 | 7:33 pm

Peraso Inc. reported worse-than-expected Q4 EPS results, causing its shares to fall by over 23%. Other stocks experienced significant movements, with notable gainers including Ontrak, Fusion Pharmaceuticals, and Spire Global, among others. Losers included Greenwave Technology Solutions, Seelos Therapeutics, and Comtech Telecommunications, with various reasons such as disappointing financial results, downgrades, and restructuring of debt.

Portfolio Pulse from Avi Kapoor

March 19, 2024 | 5:48 pm

Enveric Biosciences (NASDAQ:ENVB) shares surged after the company announced signing two non-binding term sheets with an undisclosed biotech company for out-licensing cannabinoid-COX-2 conjugate compounds for joint diseases. These agreements could potentially bring Enveric up to $82 million in milestone payments, plus royalties on future sales. The deals cover both pharmaceutical and non-pharmaceutical applications, with responsibilities for product development shifting to the licensee.

Portfolio Pulse from Vandana Singh

March 19, 2024 | 1:34 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. Ontrak, Fusion Pharmaceuticals, and Enveric Biosciences were among the top gainers, with Ontrak leading at a 173.2% increase. Conversely, Seelos Therapeutics, Acurx Pharmaceuticals, and Motus GI Holdings were the top losers, with Seelos Therapeutics dropping by 42.7%. These movements reflect the volatile nature of healthcare stocks and could be influenced by recent earnings reports and market capitalization changes.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 1:05 pm

Enveric Biosciences shares surged following the announcement of two non-binding term sheets signed with an undisclosed biotech company for out-licensing cannabinoid-COX-2 conjugate compounds for treating joint diseases.